Thus, our study aimed to comprehensively compare efficiency and safety of monotherapy with combination therapy of PDE5-Is and ABs for treating LUTS/BPH and lower ureteric stones based on existing RCTs. Here, PDE5A is linked to benign prostatic hyperplasia.